NEULAND
These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analysts
Global markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at the end of last week were at about $118 to the barrel, are now under $95. The hope clearly is that Democrat control of both chambers of the US Congress will pressure the Trump administration to pursue a diplomatic end to the conflict with Iran in the Gulf.
Stocks in news: NSE, BSE, SBI, Happiest Minds, MCX, IEX and Minda Corp
The Indian stock market continues its upward momentum, with the Nifty 50 showing a robust rally and hitting significant resistance levels. Major players like NSE and SBI have posted remarkable quarterly results, illustrating their strong profitability and revenue growth. Firms such as Happiest Minds Technologies and the Multi Commodity Exchange of India contributed positively to the market's performance.
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Indian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC faced a decline in consolidated net profit, impacted by the cigarette business, despite revenue growth. Marico saw a significant rise in net profit and expanding EBITDA margins during the quarter. Container Corporation of India reported a subdued performance with a slight decline in net profit compared to last year.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
When a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling used cars reported numbers that fell short, and the street punished the stock severely. But it is not just the clear misses. Anything that is well-owned and presents disappointing numbers is seeing double-digit cuts.
These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analysts
The last few weeks have made one thing clear. Oil prices, US bond yields, corporate earnings, and the state of the world – all point the same way. So, the market is more likely to stay in this jumpy and uncertain mood for quite some time. But then there is something called history, and it provides some interesting lessons.
- Go To Page 1
Vijay Kedia reveals multibagger playbook: How the superstar picks stocks using RISE strategy
Vijay Kedia’s investment approach is built as much around discipline as opportunity. He is willing to buy stocks after sharp declines but refuses to chase them when valuations move beyond his comfort zone. As mutual funds, family offices and other investors crowd into emerging businesses, Kedia is increasingly looking at SMEs, unlisted companies and startups for opportunities that offer attractive valuations and growth potential.
Ahead of Market: 10 things that will decide stock market action on Wednesday
Indian equities extended their decline on Tuesday, with Sensex falling 555 points and Nifty ending below 23,650. Analysts cited elevated crude prices, Fed rate hike concerns and IPO fund absorption, while technical signals suggested 23,600 as key Nifty support.
Two Trades for Today: A leading textile manufacturer for a 5.75% rise, a mid-cap pharma stock for a gain of almost 7%
Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical calls for today.
Stocks in news: Swiggy, M&M, REC, Adani Power and Bajaj Finserv
Indian stock markets closed lower on Monday, extending their losing streak for four weeks. Investor sentiment remained subdued due to rising oil prices and geopolitical tensions. Swiggy announced a stake sale in Lynks Logistics for approximately $52.4 million. Mahindra & Mahindra maintained its leadership in the domestic tractor market by volume. REC issued India's first pilot tokenized corporate bonds, receiving strong investor interest.
Muthoot FinCorp rolls out Rs 700 crore NCD issue. Here's what investors need to know
Muthoot FinCorp has launched the fifth tranche of its secured, rated and redeemable NCDs, offering effective annual yields of 8.89% to 9.25% across four tenures ranging from 24 to 72 months. The company aims to raise up to Rs 700 crore, with proceeds earmarked for onward lending, repayment or prepayment of existing borrowings and general corporate purposes.
Exclusive | How Vijay Kedia turned a Rs 250 Neuland Labs bet into nearly 100x returns
Investor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the company’s promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with solid fundamentals, which has ultimately fostered substantial wealth growth over the years.
From the ashes of bear-market: Over 125 smallcap stocks soar up to 300% from 52-week lows
Smallcap stocks have shown a stunning revival after hitting recent lows, with numerous companies experiencing value increases over double their 52-week lows. This robust recovery is backed by better earnings reports and a resurgence in investor confidence. The positive trends span multiple sectors, indicating a broad-based rebound as investors increasingly redirect their focus toward smaller companies following a challenging correction period.
Midcap Street party turns selective as 15 stocks power 50% of rally
Indian midcap and smallcap indices are near record highs currently. A few select stocks are driving most of these significant gains. This concentration indicates a selective rally rather than broad market health. Analysts suggest earnings growth and sector rotation are fueling this trend. Investors should focus on balance-sheet strength and selective stock picking.
Neuland Laboratories shares jump over 6% after 975% YoY surge in Q1 profit
Neuland Laboratories shares rose sharply on Thursday after the drugmaker reported a 975% year-on-year surge in Q1 FY27 profit to Rs 147.4 crore. Revenue more than doubled, while EBITDA jumped 448%, driven by strong commercial product sales and encouraging performance across its CMS and GDS businesses.
Neuland Laboratories shares rally 7% as profit jumps seven-fold and revenue doubles in Q4
Neuland Laboratories shares saw a significant jump following a strong Q4 performance. The company reported a massive increase in profit and revenue year-on-year. This robust financial result was driven by strong business momentum across key segments. The company is also investing in future growth through strategic initiatives.
Neuland Labs shares soar 10%, hit 52-week high after Q2 PAT spikes 201% YoY
Neuland Laboratories’ shares hit a 52-week high after the company posted stellar Q2FY26 results. PAT surged 201.6% YoY to ₹96.5 crore, revenue rose 63.7% to ₹516.1 crore, and EBITDA jumped 138.8% to ₹156.9 crore, with margins expanding 960 bps to 30.4%, driven by strong operational performance and profitability.
Buy, Sell or Hold: Nuvama initiates coverage on Neuland Laboratories; Motilal Oswal maintains buy on L&T Finance
Brokerages remain positive on select mid-cap stocks. Nuvama initiated coverage on Neuland Laboratories with a Buy rating, citing strong peptide-led growth and robust financial projections through FY28. Motilal Oswal reiterated its Buy on L&T Finance, highlighting digital gains, gold loan expansion, and expected improvements in RoA and profitability. Both stocks show promising upside potential based on growth visibility.
Neuland Laboratories shares jump 12% ahead of final dividend
Neuland Laboratories shares are experiencing a surge, trading 12% higher. This increase comes as investors anticipate a final dividend of Rs 12 per share. The record date for dividend eligibility is July 18, 2025. Technically, the stock shows a strong bullish trend. It trades above all analyzed Simple Moving Averages. The Relative Strength Index indicates neither oversold nor overbought conditions.
Will Neuland Laboratories recover after a 7% stock drop and plummeting profits?
Neuland Laboratories' shares plunged, extending losses due to investor concerns over a 59% drop in Q4 profit, despite strong guidance. Increased operating costs and reduced sales volumes triggered the decline. While the company anticipates better growth in FY26, peers have reported stronger results and promising outlooks, further impacting investor sentiment.
Capital Group exits Neuland Labs; sells 3.77 pc stake for Rs 756 crore
Financial services company Capital Group on Thursday exited Neuland Laboratories by selling 3.77 per cent stake in the company for Rs 756 crore through an open market transaction. Neuland is a leading global API Contract Development and Manufacturing Organisation.
Neuland Laboratories shares crack 7% after likely 3.8% stake offloaded via block deal
Neuland Laboratories share price: Neuland Laboratories shares plunged 7.2% on Thursday after a block deal involving 3.8% of its shares was executed at a significant discount. The floor price for the deal was set at Rs 15,428, nearly 9% below the previous day's closing price.
Small-cap selloff, poor Q1 hit Neuland hard
From a record high of ₹2,840 in April, Neuland Laboratories has sunk to nearly half that level and is hitting back-to-back lower circuits in the past few days.
Buy Neuland Laboratories, target Rs 920: HDFC Securities
Neuland Laboratories is a smallcap company, operating in pharmaceuticals and health care sector.
Buy Neuland Laboratories, target Rs 1000: HDFC Securities
Buy Neuland Laboratories Ltd. at a price target of Rs 1000..
US regulator makes 2 observations at Neuland Labs' facility
"The USFDA inspected Unit 1, manufacturing facility at Bonthapally, Hyderabad of the company from April 3-7, 2017. At the end of the inspection, there were 2 observations given under form 483," Neuland Laboratories said.
Evolvence India Fund to exit Neuland Labs; puts entire stake of 33 per cent on sale
Vishy Chebrol, one of the founders and managing directors of InvAscent, confirmed the fund is looking at exiting its investment in the company.
Load More
